February 16, 2018 / 9:37 AM / 8 months ago

BRIEF-Oncolys BioPharma invests in US Biotech Venture Specialized in Development of Novel Oncolytic Adenovirus

Feb 16 (Reuters) - Oncolys BioPharma Inc

* Says it will enter into an investment and share transfer agreement with Unleash Immuno Oncolytics, Inc., a biotech venture specialized in development of novel oncolytic adenovirus

* Says it agrees to purchase $3 million convertible bonds issued by Unleash with the expected voting rights ratio of approximately 27 percent, when fully converted

* Says it also agrees to purchase 294,118 ordinary shares of Precision Virologics held by Unleash for $330,000, which will increase Oncolys’ voting rights ratio of Precision to 23 percent, approximately

Source text in Japanese:goo.gl/y23PMq

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below